^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + ceralasertib (AZD6738) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts
Published date:
11/17/2020
Excerpt:
...pts with advanced HER2- BRCAm BC (BRCAm group)...Dose of ola+cer as ola 300 mg bid daily...In the BRCAm group, 13 (35%) pts achieved a confirmed response (including 1 complete response), 17 (46%) stable disease and 7 (19%) pts disease progression…
Trial ID:
